�鶹Ů��

Almost 1 in 4 dollars in takeovers this year involved a company in healthcare, and the size of those deals is immense. The total value of healthcare mergers and acquisitions in the United States has more than tripled compared with five years ago, according to the data firm Dealogic. Even in the face of rising interest rates, which would make deal-making more expensive, business insiders see few reasons why momentum in the healthcare sector will ease any time soon. (Murphy, 11/15)

The investing world is riddled with conflicts of interest that can surprise even the most sophisticated investor. Learning that lesson the hard way are holders of an instrument issued in 2011 when Sanofi, the giant French pharmaceutical company, took over Genzyme, a biotech concern based in Cambridge, Mass. (Morgenson, 11/13)

Mylan NV suffered defeat Friday in a landmark hostile takeover bid, dealing a blow to the generic-drug maker and casting doubt on a pharmaceutical sector that has driven a surge in global deal making. Perrigo Co. shareholders rejected Mylan’s $26 billion takeover offer, the companies said Friday. (Hoffman and Mattioli, 11/13)

Amid speculation that the U.S. Treasury would cast a skeptical eye on any deal that Pfizer Inc. and Allergan PLC might reach that would move Pfizer’s headquarters outside the U.S., Citigroup Inc. analyst Liav Abraham is weighing in on what exactly the Treasury could do to block a deal. ... Ms. Abraham said it wouldn’t be a surprise if Treasury sought to block such a deal “given the high political sensitivity surrounding the redomicile of Pfizer to a lower tax jurisdiction.” (Farrell, 11/13)